WHO Drug Information Vol. 17, No. 1, 2003
(2003; 77 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoReports on Individual Drugs
Abrir esta carpeta y ver su contenidoVaccines and Biomedicines
Abrir esta carpeta y ver su contenidoCurrent Topics
Cerrar esta carpetaSafety Issues
Ver el documentoWHO Drug Dictionary: new structure - new focus
Ver el documentoTramadol - safety experience
Ver el documentoMinocycline and intracranial hypertension
Ver el documentoNeuropsychiatric events: celecoxib and rofecoxib
Ver el documentoLinezolid: peripheral neuropathy
Ver el documentoZonisamide and visual hallucinations
Ver el documentoSalmeterol study halted
Ver el documentoLabelling and manufacturing of dietary supplements
Ver el documentoDietary supplements containing ephedra
Ver el documentoTopical use of Lindane
Abrir esta carpeta y ver su contenidoEssential Medicines
Abrir esta carpeta y ver su contenidoRegulatory and Safety Action
Abrir esta carpeta y ver su contenidoRecent Publications and Sources of Information
Ver el documentoProposed International Nonproprietary Names: List 88
Ver el documentoAnnex 1 - PROCEDURE FOR THE SELECTION OF RECOMMENDED INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES*
Ver el documentoAnnex 2 - GENERAL PRINCIPLES FOR GUIDANCE IN DEVISING INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES*
Ver el documentoAnnexe 1 - PROCEDURE A SUIVRE EN VUE DU CHOIX DE DENOMINATIONS COMMUNES INTERNATIONALES RECOMMANDEES POUR LES SUBSTANCES PHARMACEUTIQUES
Ver el documentoAnnexe 2 - DIRECTIVES GENERALES POUR LA FORMATION DE DENOMINATIONS COMMUNES INTERNATIONALES APPLICABLES AUX SUBSTANCES PHARMACEUTIQUES*
Ver el documentoAnexo 1 - PROCEDIMIENTO DE SELECCION DE DENOMINACIONES COMUNES INTERNACIONALES RECOMENDADAS PARA LAS SUSTANCIAS FARMACEUTICAS
Ver el documentoAnexo 2 - PRINCIPIOS GENERALES DE ORIENTACION PARA FORMAR DENOMINACIONES COMUNES INTERNACIONALES PARA SUSTANCIAS FARMACEUTICAS*
 

Labelling and manufacturing of dietary supplements

The Food and Drug Administration has proposed a new regulation to require current good manufacturing practices (cGMPs) in manufacturing, packing and holding of dietary supplements. The proposed rule would establish standards to ensure that dietary supplements and dietary ingredients are not adulterated with contaminants or impurities, and are labelled to reflect the active and other ingredients in the product.

This proposed rule includes requirements for designing and constructing physical plants, establishing quality control procedures, and testing manufactured dietary ingredients and dietary supplements. It also includes proposed requirements for maintaining records and for handling consumer complaints related to cGMPs.

Under the cGMP proposal, manufacturers would be required to evaluate the identity, purity, quality, strength, and composition of their dietary ingredients and dietary supplements. FDA is soliciting comments from the public and industry on this proposed regulation

Reference: http://www.fda.gov

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013